TY - JOUR
T1 - Pros and cons of pre-emptive screening programmes before peanut introduction in infancy
AU - Abrams, Elissa M.
AU - Brough, Helen A.
AU - Keet, Corinne
AU - Shaker, Marcus S.
AU - Venter, Carina
AU - Greenhawt, Matthew
N1 - Funding Information:
EMA reports moderator fees from Novartis, outside of the submitted work. HAB reports advisory board consultancy work for DBV Technologies, and research support and travel expense reimbursement for investigator meetings from ThermoScientific. CV reports personal fees from Danone, Mead Johnson Nutrition, Abbott, Nestle, DBV Technologies, and Lil Mixins, outside the submitted work. MG is supported by grant #5K08HS024599–02 from the Agency for Healthcare Research and Quality, is an expert panel and coordinating committee member of the US National Institute of Allergy and Infectious Diseases-sponsored Guidelines for Peanut Allergy Prevention, has served as a consultant for the Canadian Transportation Agency, Thermo Fisher, Intrommune, and Aimmune Therapeutics, is a member of physician and medical advisory boards for Aimmune Therapeutics, DBV Technologies, Sanofi Genzyme, Genentech, GlaxoSmithKline, Nutricia, Kaleo Pharmaceutical, Nestle, Aquestive, Allergy Therapeutics, Allergenis, Aravax, Prota, and Monsanto, is a member of the scientific advisory council for the National Peanut Board, has received honorarium for lectures from Thermo Fisher, Aimmune, DBV Technologies, Before Brands, multiple state allergy societies, the American College of Allergy Asthma and Immunology, the European Academy of Allergy and Clinical Immunology, is an associate editor for the Annals of Allergy, Asthma, and Immunology, and is a member of the Joint Taskforce on Allergy Practice Parameters. CK and MSS declare no competing interests.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/7
Y1 - 2020/7
N2 - Peanut allergy is an important public health concern and causes substantial psychosocial comorbidity. Although fatal anaphylaxis is rare (occurring at 0·03–0·3 per million person-years in the general population), peanuts are one of the most frequent causes of food allergy mortality. The Learning Early About Peanut study transformed prevention of peanut allergy by showing that early introduction of peanut into the diet of children at high risk (ie, those with an egg allergy or severe eczema) reduced the relative risk of peanut allergy at age 5 years by 81%. Following publication of this study, the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, convened an expert panel, which recommended that, for infants with severe eczema or egg allergy, health professionals should strongly consider evaluation with peanut-specific serological IgE or skin prick test (or both) and, if necessary, an oral food challenge before peanut introduction. In the USA, depending on test results, peanut-containing foods are recommended to be introduced from age 4–6 months in infants with severe eczema or egg allergy. Early introduction to peanuts is also advocated for children with either mild to moderate or no eczema, and in children who are not allergic to egg, but without screening before peanut introduction. However, the NIAID addendum guidelines contrast with other international approaches that do not advocate for allergy screening at a population level before introducing peanuts into infants' diets. In this Review, we evaluate the advantages and disadvantages of a pre-emptive screening approach before the early introduction of peanuts in infants at high risk of peanut allergy.
AB - Peanut allergy is an important public health concern and causes substantial psychosocial comorbidity. Although fatal anaphylaxis is rare (occurring at 0·03–0·3 per million person-years in the general population), peanuts are one of the most frequent causes of food allergy mortality. The Learning Early About Peanut study transformed prevention of peanut allergy by showing that early introduction of peanut into the diet of children at high risk (ie, those with an egg allergy or severe eczema) reduced the relative risk of peanut allergy at age 5 years by 81%. Following publication of this study, the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, convened an expert panel, which recommended that, for infants with severe eczema or egg allergy, health professionals should strongly consider evaluation with peanut-specific serological IgE or skin prick test (or both) and, if necessary, an oral food challenge before peanut introduction. In the USA, depending on test results, peanut-containing foods are recommended to be introduced from age 4–6 months in infants with severe eczema or egg allergy. Early introduction to peanuts is also advocated for children with either mild to moderate or no eczema, and in children who are not allergic to egg, but without screening before peanut introduction. However, the NIAID addendum guidelines contrast with other international approaches that do not advocate for allergy screening at a population level before introducing peanuts into infants' diets. In this Review, we evaluate the advantages and disadvantages of a pre-emptive screening approach before the early introduction of peanuts in infants at high risk of peanut allergy.
UR - http://www.scopus.com/inward/record.url?scp=85086445035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086445035&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(20)30029-8
DO - 10.1016/S2352-4642(20)30029-8
M3 - Review article
C2 - 32562634
AN - SCOPUS:85086445035
SN - 2352-4642
VL - 4
SP - 526
EP - 535
JO - The Lancet Child and Adolescent Health
JF - The Lancet Child and Adolescent Health
IS - 7
ER -